email_pop up_pop
X

EMAIL US

X
up_inner

UNITARY PATENT

In 2012 Member States and the European Parliament agreed on the "patent package" - a legislative initiative consisting of two...

find out more

IP in the digital age: a tricky path ahead for pharma companies?

James Cross, Partner at Maucher Jenkins, has contributed to an article published by Life Sciences Intellectual Property Review concerning IP protection in the world of digital health and the need for pharmaceutical companies to adjust in the digital age.

You can read the full article from LSIPR by clicking here




Tuesday, September 20, 2016